Literature DB >> 28028749

Oral cyclophosphamide was effective for Coombs-negative autoimmune hemolytic anemia in CD16+CD56- chronic lymphoproliferative disorder of NK-cells.

Nodoka Sekiguchi1,2, Sayaka Nishina3, Toru Kawakami3, Hitoshi Sakai3, Noriko Senoo3, Yasushi Senoo3, Toshiro Ito4, Hiroshi Saito5, Hideyuki Nakazawa3, Tomonobu Koizumi6, Fumihiro Ishida3,7.   

Abstract

An 84-year-old woman was referred to our hospital presenting anemia. Her hemoglobin level was 5.8 g/dL, and white blood cell count was 9400/μL, consisting of 82% lymphocytes. Given the lymphocyte phenotype (CD2+, CD3-, CD16+, and CD56-) and negative whole blood EBV viral load, we made a diagnosis of chronic lymphoproliferative disorder of NK cells (CLPD-NK). We suspected hemolytic anemia because of the high levels of reticulocytes in the peripheral blood and the low haptoglobin value. Although the direct Coombs test was negative and there was no cold agglutination, we examined her red-blood-cell-bound IgG (RBC-IgG), which was elevated. She was diagnosed as having as Coombs-negative autoimmune hemolytic anemia (AIHA). We report the effectiveness of oral cyclophosphamide for Coombs-negative autoimmune hemolytic anemia in CLPD-NK.

Entities:  

Keywords:  Chronic lymphoproliferative disorder of NK cells; Coombs-negative autoimmune hemolytic anemia; Pure red cell aplasia; Signal transducer and activator of transcription 3

Mesh:

Substances:

Year:  2016        PMID: 28028749     DOI: 10.1007/s12185-016-2170-4

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  27 in total

1.  Cut-off value of red-blood-cell-bound IgG for the diagnosis of Coombs-negative autoimmune hemolytic anemia.

Authors:  Toyomi Kamesaki; Takashi Oyamada; Mitsuhiro Omine; Keiya Ozawa; Eiji Kajii
Journal:  Am J Hematol       Date:  2009-02       Impact factor: 10.047

2.  Large granular lymphocyte disorders: new etiopathogenetic clues as a rationale for innovative therapeutic approaches.

Authors:  Renato Zambello; Gianpietro Semenzato
Journal:  Haematologica       Date:  2009-10       Impact factor: 9.941

3.  Pure red-cell aplasia associated with clonal expansion of granular lymphocytes expressing killer-cell inhibitory receptors.

Authors:  R Handgretinger; A Geiselhart; A Moris; R Grau; O Teuffel; W Bethge; L Kanz; P Fisch
Journal:  N Engl J Med       Date:  1999-01-28       Impact factor: 91.245

4.  How I treat LGL leukemia.

Authors:  Thierry Lamy; Thomas P Loughran
Journal:  Blood       Date:  2010-12-29       Impact factor: 22.113

Review 5.  Large granular lymphocytic leukaemia pathogenesis and management.

Authors:  Claire Dearden
Journal:  Br J Haematol       Date:  2010-12-15       Impact factor: 6.998

6.  A long-term study of patients with chronic natural killer cell lymphocytosis.

Authors:  G R Rabbani; R L Phyliky; A Tefferi
Journal:  Br J Haematol       Date:  1999-09       Impact factor: 6.998

Review 7.  Large granular lymphocyte leukemia.

Authors:  Lubomir Sokol; Thomas P Loughran
Journal:  Oncologist       Date:  2006-03

Review 8.  Progress in understanding and managing natural killer-cell malignancies.

Authors:  Kazuo Oshimi
Journal:  Br J Haematol       Date:  2007-10-03       Impact factor: 6.998

9.  Cyclosporine A alleviates severe anaemia associated with refractory large granular lymphocytic leukaemia and chronic natural killer cell lymphocytosis.

Authors:  K C Bible; A Tefferi
Journal:  Br J Haematol       Date:  1996-05       Impact factor: 6.998

10.  Immunosuppressive therapy of LGL leukemia: prospective multicenter phase II study by the Eastern Cooperative Oncology Group (E5998).

Authors:  T P Loughran; L Zickl; T L Olson; V Wang; D Zhang; H L M Rajala; Z Hasanali; J M Bennett; H M Lazarus; M R Litzow; A M Evens; S Mustjoki; M S Tallman
Journal:  Leukemia       Date:  2014-09-13       Impact factor: 11.528

View more
  1 in total

1.  STAT3 mutations in natural killer cells are associated with cytopenia in patients with chronic lymphoproliferative disorder of natural killer cells.

Authors:  Toru Kawakami; Nodoka Sekiguchi; Jun Kobayashi; Taku Yamane; Sayaka Nishina; Hitoshi Sakai; Yukio Hirabayashi; Hideyuki Nakazawa; Fumihiro Ishida
Journal:  Int J Hematol       Date:  2019-03-11       Impact factor: 2.490

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.